Menu
GeneBe

GALK1

galactokinase 1

Basic information

Region (hg38): 17:75751593-75765236

Previous symbols: [ "GALK" ]

Links

ENSG00000108479NCBI:2584OMIM:604313HGNC:4118Uniprot:P51570AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • galactokinase deficiency (Definitive), mode of inheritance: AR
  • galactokinase deficiency (Definitive), mode of inheritance: AR
  • galactokinase deficiency (Strong), mode of inheritance: AR
  • galactokinase deficiency (Supportive), mode of inheritance: AR
  • galactokinase deficiency (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Galactosemia IIARBiochemicalIndividuals may manifest with early-onset cataracts, and dietary measures (galactose/lactose restricted diet) can be effective; The presence of pseudotumor cerebri has been described, and awareness may allow prompt recognition and managementBiochemical; Neurologic; Ophthalmologic3043741; 5109408; 5034870; 74495; 490246; 7670469; 8908517; 10570908; 10521295; 10790206; 11139256; 11978884; 12705493; 15024738; 17517531; 20405025; 21290184; 22154682; 22632133

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GALK1 gene.

  • Deficiency of galactokinase (375 variants)
  • not provided (24 variants)
  • Inborn genetic diseases (15 variants)
  • not specified (10 variants)
  • GALK1-related condition (1 variants)
  • Junctional epidermolysis bullosa with pyloric atresia (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GALK1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
161
clinvar
4
clinvar
166
missense
2
clinvar
4
clinvar
66
clinvar
1
clinvar
2
clinvar
75
nonsense
6
clinvar
18
clinvar
24
start loss
1
clinvar
1
clinvar
2
frameshift
11
clinvar
18
clinvar
29
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
3
clinvar
5
clinvar
8
splice region
15
15
non coding
1
clinvar
4
clinvar
4
clinvar
36
clinvar
7
clinvar
52
Total 24 50 73 198 13

Highest pathogenic variant AF is 0.0000853

Variants in GALK1

This is a list of pathogenic ClinVar variants found in the GALK1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
17-75751900-A-G Likely benign (Oct 19, 2018)1215254
17-75752027-C-T Benign (Jul 09, 2018)1287294
17-75752165-C-T Junctional epidermolysis bullosa with pyloric atresia • ITGB4-related disorder Conflicting classifications of pathogenicity (Jan 18, 2024)891167
17-75752168-C-T Likely benign (Dec 18, 2022)2911733
17-75752187-C-T Likely benign (Oct 27, 2023)2813455
17-75752189-T-C Junctional epidermolysis bullosa with pyloric atresia Uncertain significance (Jan 13, 2018)325184
17-75752190-G-A Conflicting classifications of pathogenicity (Jan 30, 2024)1800870
17-75752199-G-C Likely benign (Dec 01, 2023)2700095
17-75752220-C-T Likely benign (Sep 18, 2023)3005971
17-75752221-C-T Junctional epidermolysis bullosa with pyloric atresia Pathogenic (Jan 08, 2019)14742
17-75752238-G-A Junctional epidermolysis bullosa with pyloric atresia Conflicting classifications of pathogenicity (Nov 11, 2023)325185
17-75752241-C-T Junctional epidermolysis bullosa with pyloric atresia Benign/Likely benign (Jan 31, 2024)325186
17-75752245-C-A Likely benign (Jun 01, 2021)1622476
17-75752245-C-T Inborn genetic diseases Uncertain significance (Dec 05, 2022)2086987
17-75752262-C-T Likely benign (Oct 22, 2023)2987887
17-75752263-C-T Inborn genetic diseases Uncertain significance (May 17, 2023)1905269
17-75752264-G-A Junctional epidermolysis bullosa with pyloric atresia • Inborn genetic diseases Uncertain significance (Oct 14, 2023)891168
17-75752265-C-A Likely benign (Nov 29, 2023)2908234
17-75752265-C-T Junctional epidermolysis bullosa with pyloric atresia;Epidermolysis bullosa, junctional 5A, intermediate Likely benign (Sep 08, 2023)749786
17-75752270-C-T Uncertain significance (Jan 16, 2022)1925452
17-75752271-G-A Likely benign (Dec 14, 2023)1559364
17-75752271-G-T Likely benign (Apr 20, 2023)2858046
17-75752280-G-A Likely benign (Dec 19, 2023)2801856
17-75752281-C-T Inborn genetic diseases Uncertain significance (Aug 04, 2023)2594211
17-75752282-G-A Inborn genetic diseases Uncertain significance (Aug 21, 2023)2620142

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GALK1protein_codingprotein_codingENST00000588479 814118
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.00001040.8121256920181257100.0000716
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.5932212470.8940.00001642428
Missense in Polyphen6381.4430.77354803
Synonymous-0.003331101101.000.00000726863
Loss of Function1.301015.50.6446.66e-7183

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0002120.000209
Ashkenazi Jewish0.00009940.0000992
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00006350.0000616
Middle Eastern0.000.00
South Asian0.00009900.0000980
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Major enzyme for galactose metabolism.;
Disease
DISEASE: Galactosemia II (GALCT2) [MIM:230200]: Autosomal recessive deficiency characterized by congenital cataracts during infancy and presenile cataracts in the adult population. The cataracts are secondary to accumulation of galactitol in the lenses. {ECO:0000269|PubMed:10521295, ECO:0000269|PubMed:10790206, ECO:0000269|PubMed:11139256, ECO:0000269|PubMed:11231902, ECO:0000269|PubMed:12694189, ECO:0000269|PubMed:15024738}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Galactose metabolism - Homo sapiens (human);Amino sugar and nucleotide sugar metabolism - Homo sapiens (human);Galactosemia III;Galactosemia II (GALK);Galactose Metabolism;Nucleotide Sugars Metabolism;Galactosemia;Metabolism of carbohydrates;Metabolism;D-galactose degradation V (Leloir pathway);Galactose catabolism;Galactose metabolism (Consensus)

Intolerance Scores

loftool
0.254
rvis_EVS
-0.84
rvis_percentile_EVS
11.18

Haploinsufficiency Scores

pHI
0.0808
hipred
N
hipred_score
0.251
ghis
0.611

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.923

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Galk1
Phenotype
vision/eye phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
galactose metabolic process;galactose catabolic process;galactitol metabolic process;galactose catabolic process via UDP-galactose;carbohydrate phosphorylation;glycolytic process from galactose
Cellular component
cytoplasm;cytosol;membrane;extracellular exosome
Molecular function
galactokinase activity;ATP binding;galactose binding